Abstract:There has been a long-standing controversy regarding the number of lymph nodes (LNs) examined intraoperatively for accurate lymphatic staging and significantly better survival of patients with pancreatic ductal adenocarcinoma (PDAC), and no consensus has been reached for the elderly with the age of over 75 years. Given these, the present study aims to investigate the appropriate number of examined lymph nodes (ELNs) for elderly patients mentioned above. In this study, population-based data on 20,125 patients in 2000 to 2019 from the Surveillance, Epidemiology, and End Results database were reviewed retrospectively. The eighth edition staging system of the American Joint Committee on Cancer (AJCC) was applied. Propensity score matching (PSM) was performed to reduce the effects of multiple biases. By using binomial probability law and maximally selected rank statistics, the minimum number of ELN (MNELN) for accurate nodal involvement assessment and optimal ELN number for significantly better survival were calculated, respectively. In addition, Kaplan-Meier curves and Cox proportional hazard regression models were constructed for further survival analysis. As a result, 6623 patients were enrolled in total in the study. Elderly patients had fewer lymph node metastases and a smaller lymph node ratio (LNR) (all P<0.05). However, poorer overall survival (OS) and cancer-specific survival (CSS) of elderly patients were observed in each pN stage (all P<0.05), except for CSS in N2. The proportions of N2 and N0 stages increased and decreased respectively with increasing number of ELN significantly. MNELN for accurate nodal assessment was 19 according to binomial probability law, and the optimal ELN number for significantly better survival was 17. Additionally, the number of ELN (<17 or ≥17) was also considered a strong prognostic predictor for elderly PDAC patients (≥75 years) in the Cox proportional hazard regression model (Overall survival: hazard ratio [HR]=0.74, 95% confidence interval [CI]: 0.65-0.83, P<0.001; Cancer-specific survival: HR=0.75, 95% CI: 0.66-0.85, P<0.001). In conclusion, extended lymphadenectomy is suitable for elderly PDAC patients undergoing curative-intent surgery owing to an accurate assessment of nodal status and improved long-term prognosis. However, a random, prospective clinical trial is warranted before the recommendation of extended lymphadenectomy for the elderly.

Original study: The rescue staging for pancreatic ductal adenocarcinoma with inadequate examined lymph nodes

The Relationship Between the Number of Examined Lymph Nodes and the Efficacy of Chemotherapy for Gastric Cancer

Number of Positive Lymph Nodes is Superior to LNR and LODDS for Predicting the Prognosis of Pancreatic Neuroendocrine Neoplasms

Proposal Of The Optimal Numbers Of Examined And Positive Lymph Nodes To The 8th Edition Of American Joint Committee On Cancer (Ajcc) Staging For 758 Patients With Distal Cholangiocarcinoma

Impact of examined lymph node count on prognosis in patients with lymph node-negative pancreatic body/tail ductal adenocarcinoma.

Lymph node examination and survival in resected pancreatic ductal adenocarcinoma: retrospective study

Validation and Modification of the AJCC 8th TNM Staging System for Pancreatic Ductal Adenocarcinoma in a Chinese Cohort: A Nationwide Pancreas Data Center Analysis

Determining the Optimal Number of Examined Lymph Nodes for Accurate Staging of Pancreatic Cancer: an Analysis Using the Nodal Staging Score Model.

Comparison of prognostic prediction between nomogram based on lymph node ratio and AJCC 8th staging system for patients with resected pancreatic head carcinoma: a SEER analysis

Optimized Modification of the Eighth Edition of AJCC TNM Staging System for Resected Pancreatic Ductal Adenocarcinoma.

Significance of Examined Lymph Node Number in Accurate Staging and Long-Term Survival in Resected Stage I-II Pancreatic Cancer: More is Better? A Large International Population-Based Cohort Study.

Proposed Modification of the 8th Edition of the AJCC Staging System for Pancreatic Ductal Adenocarcinoma

AB115. P089. Comparison of Prognostic Prediction Between Nomogram Based on Lymph Node Ratio and AJCC 8th Staging System for Patients with Resected Pancreatic Head Carcinoma: a SEER Analysis

A Novel Criterion for Lymph Nodes Dissection in Distal Pancreatectomy for Ductal Adenocarcinoma: A Population Study of the US SEER Database

Role of Lymph Node Resection and Histopathological Evaluation in Accurate Staging of Nonfunctional Pancreatic Neuroendocrine Tumors: How Many Are Enough?

Equipping the American Joint Committee on Cancer Staging for Resectable Pancreatic Ductal Adenocarcinoma with Tumor Grade: A Novel Staging System

Should a Standard Lymphadenectomy During Pancreatoduodenectomy Exclude Para-Aortic Lymph Nodes for All Cases of Resectable Pancreatic Head Cancer? A Consensus Statement by the Chinese Study Group for Pancreatic Cancer (CSPAC).

A Novel Scoring System Predicts Postsurgical Survival and Adjuvant Chemotherapeutic Benefits in Patients with Pancreatic Adenocarcinoma: Implications for AJCC-TNM Staging

Exploration of the Lymphadenectomy Strategy for Elderly Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Resection.

Association Between Lymph Node Examination and Nodal Staging for Pancreatic Adenocarcinoma: A Population-Based Analysis.

Prognostic Value of a New Staging System Based on the Retrieved Number and Metastatic Rate of LNs in Gastric Cancer with ≤15 Retrieved LNs.